Venus Remedies Ltd
Venus Remedies Ltd is an Indian Pharmaceutical company with a presence in domestic and international markets. It is primarily engaged in the business of pharmaceutical products manufacturing.[1]
- Market Cap ₹ 513 Cr.
- Current Price ₹ 384
- High / Low ₹ 407 / 145
- Stock P/E 25.7
- Book Value ₹ 365
- Dividend Yield 0.00 %
- ROCE 8.03 %
- ROE 6.24 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.05 times its book value
- Company has delivered good profit growth of 25.3% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.77% over last 3 years.
- Debtor days have increased from 29.7 to 58.0 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
397 | 452 | 515 | 443 | 392 | 375 | 355 | 299 | 316 | 511 | 574 | 534 | 527 | |
291 | 333 | 382 | 356 | 312 | 328 | 312 | 265 | 273 | 464 | 505 | 473 | 472 | |
Operating Profit | 106 | 118 | 133 | 87 | 80 | 47 | 44 | 34 | 43 | 47 | 69 | 62 | 55 |
OPM % | 27% | 26% | 26% | 20% | 20% | 13% | 12% | 11% | 14% | 9% | 12% | 12% | 10% |
0 | 0 | 0 | 1 | 1 | 1 | 1 | -4 | -5 | 41 | 8 | 10 | 12 | |
Interest | 27 | 24 | 29 | 41 | 37 | 34 | 35 | 25 | 13 | 13 | -0 | -0 | 0 |
Depreciation | 24 | 32 | 39 | 45 | 40 | 39 | 33 | 33 | 31 | 34 | 33 | 31 | 29 |
Profit before tax | 55 | 63 | 66 | 2 | 3 | -25 | -23 | -28 | -6 | 41 | 45 | 40 | 38 |
Tax % | 9% | 9% | 7% | -123% | 60% | 18% | -13% | 4% | -31% | -32% | -10% | 28% | |
50 | 57 | 61 | 5 | 1 | -20 | -27 | -27 | -8 | 54 | 49 | 29 | 20 | |
EPS in Rs | 51.35 | 54.21 | 53.27 | 3.98 | 1.05 | -16.40 | -21.54 | -21.97 | -6.67 | 43.97 | 36.65 | 21.67 | 14.92 |
Dividend Payout % | 6% | 6% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | 9% |
3 Years: | 19% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | -7% |
5 Years: | 25% |
3 Years: | 184% |
TTM: | -31% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | 55% |
3 Years: | 42% |
1 Year: | 97% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 5% |
3 Years: | 9% |
Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 |
Reserves | 300 | 377 | 456 | 455 | 433 | 382 | 356 | 329 | 320 | 374 | 436 | 465 | 474 |
220 | 271 | 288 | 319 | 327 | 308 | 302 | 294 | 216 | 48 | 39 | 39 | 39 | |
56 | 71 | 81 | 60 | 63 | 65 | 78 | 97 | 96 | 113 | 91 | 92 | 112 | |
Total Liabilities | 587 | 729 | 836 | 845 | 834 | 767 | 748 | 732 | 644 | 547 | 579 | 609 | 638 |
336 | 381 | 416 | 426 | 434 | 389 | 370 | 347 | 271 | 244 | 225 | 200 | 189 | |
CWIP | 23 | 48 | 68 | 78 | 80 | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 26 |
Investments | 29 | 29 | 29 | 29 | 29 | 29 | 0 | 0 | 0 | 0 | 0 | 20 | 3 |
199 | 272 | 323 | 312 | 291 | 283 | 314 | 320 | 348 | 277 | 329 | 363 | 421 | |
Total Assets | 587 | 729 | 836 | 845 | 834 | 767 | 748 | 732 | 644 | 547 | 579 | 609 | 638 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
38 | 51 | 53 | 67 | 42 | 62 | 52 | 44 | 78 | 132 | 41 | 28 | |
-94 | -102 | -94 | -67 | 3 | -18 | -11 | -11 | -5 | 56 | -17 | -51 | |
56 | 55 | 39 | -0 | -46 | -44 | -40 | -35 | -72 | -162 | -9 | -0 | |
Net Cash Flow | -0 | 3 | -2 | -1 | -0 | 0 | 0 | -2 | 1 | 26 | 15 | -23 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 41 | 43 | 44 | 49 | 50 | 41 | 45 | 38 | 34 | 12 | 19 | 58 |
Inventory Days | 155 | 175 | 173 | 189 | 210 | 230 | 242 | 283 | 282 | 130 | 121 | 123 |
Days Payable | 20 | 25 | 34 | 35 | 36 | 50 | 48 | 67 | 70 | 74 | 48 | 53 |
Cash Conversion Cycle | 176 | 193 | 183 | 203 | 223 | 220 | 239 | 254 | 246 | 67 | 93 | 129 |
Working Capital Days | 91 | 104 | 118 | 149 | 180 | 164 | 143 | 130 | 171 | 68 | 84 | 118 |
ROCE % | 17% | 15% | 13% | 6% | 5% | 1% | 2% | 1% | 3% | 6% | 10% | 8% |
Documents
Announcements
- Venus Remedies Granted Market Authorizations For Enoxaparin In Azerbaijan. 1d
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1 Dec - Venus Remedies Limited granted Market Authorisations in Saudi Arabia and Philippines
- Unaudited Financial Results For The Quarter Ended On 30Th Sep 2023. 25 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Nov - Newspaper publication of UFR as on 30th Sep 2023.
- Submission Of Unaudited Financial Results For The Period Ended On 30Th September 2023. 9 Nov
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Therapeutic Areas
The company manufactures and sells a very wide range of pharmaceutical products in therapeutic segments like Anti-infective (antibiotics), oncology, neurology, pain management, skin & wound care, anti-microbial resistance, etc.[1]